CG Oncology, Inc. $CGON Shares Purchased by First Trust Advisors LP

Posted by George Bondi on Jul 30th, 2026

First Trust Advisors LP increased its stake in shares of CG Oncology, Inc. (NASDAQ:CGON – Free Report) by 83.3% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 333,192 shares of the company’s stock after purchasing an additional 151,394 shares during the period. First Trust Advisors LP’s holdings in CG Oncology were worth $22,550,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. NFSG Corp purchased a new stake in CG Oncology in the first quarter valued at approximately $34,000. Whittier Trust Co. of Nevada Inc. purchased a new position in shares of CG Oncology during the fourth quarter worth $27,000. Comerica Bank boosted its position in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after buying an additional 515 shares during the period. Fifth Third Bancorp purchased a new position in shares of CG Oncology during the first quarter worth $74,000. Finally, KBC Group NV acquired a new stake in shares of CG Oncology in the first quarter valued at $78,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

Insiders Place Their Bets

In other CG Oncology news, Director Leonard E. Post sold 5,000 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total value of $350,000.00. Following the sale, the director owned 5,000 shares of the company’s stock, valued at $350,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Brian Guan-Chyun Liu purchased 371,085 shares of CG Oncology stock in a transaction on Thursday, June 25th. The stock was bought at an average cost of $66.87 per share, for a total transaction of $24,814,453.95. Following the transaction, the director directly owned 1,886,236 shares in the company, valued at $126,132,601.32. This represents a 24.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 37,129 shares of company stock worth $2,663,817 in the last quarter. 4.80% of the stock is owned by company insiders.

CG Oncology Stock Down 4.8%

NASDAQ:CGON opened at $69.12 on Thursday. CG Oncology, Inc. has a 52 week low of $23.65 and a 52 week high of $77.00. The company has a fifty day simple moving average of $65.75 and a two-hundred day simple moving average of $63.11. The company has a market cap of $6.10 billion, a price-to-earnings ratio of -29.67 and a beta of 0.22.

CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to analyst estimates of $0.45 million. On average, analysts expect that CG Oncology, Inc. will post -2.89 EPS for the current year.

Wall Street Analyst Weigh In

CGON has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of CG Oncology in a report on Friday, July 17th. Wedbush raised their target price on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Truist Financial reaffirmed a “buy” rating and issued a $82.00 target price (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. Wolfe Research started coverage on shares of CG Oncology in a research note on Tuesday, May 19th. They set a “peer perform” rating on the stock. Finally, JPMorgan Chase & Co. increased their price target on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.73.

Check Out Our Latest Stock Report on CGON

About CG Oncology

(Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.